Table 4.
Multivariate analysis of the impact of clinic-pathological features on the survival of oral squamous cell carcinoma patients based on pathological stage and subsites (the tongue and the buccal mucosa only).
| All (n = 1383) | All Stage I & II (n = 582) | All Stage III & IV (n = 801) | Tongue Stage I & II (n = 188) | Tongue Stage III and IV (n = 229) | Buccal Stage I & II (n = 235) | Buccal Stage III & IV (n = 321) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| Age >50 years | 0.83 | 0.67–1.03 | 0.81 | 0.51–1.29 | 0.81 | 0.64–1.04 | 0.69 | 0.29–1.63 | 0.96 | 0.62–1.47 | 0.68 | 0.34–1.34 | 0.98 | 0.68–1.43 |
| Tumor grade | ||||||||||||||
| MD vs. WD | 1.72 | 0.96–3.11 | 1.63 | 0.70–3.84 | 1.66 | 0.73–3.77 | 0.78 | 0.16–3.82 | >1000 | 0–>10000 | 3.08 | 0.72–13.13 | 2.17 | 0.52–9.00 |
| PD vs. WD | 2.30 | 1.25–4.25 | 2.17 | 0.83–5.67 | 2.16 | 0.93–5.01 | 1.85 | 0.34–9.97 | >1000 | 0–>10000 | 4.75 | 0.98–22.92 | 3.01 | 0.71–12.70 |
| PNI | 1.36 | 1.07–1.72 | 2.36 | 1.31–4.21 | 1.24 | 0.96–1.60 | 3.81 | 1.38–10.54 | 1.29 | 0.83–2.00 | 0.76 | 0.22–2.59 | 1.10 | 0.72–1.67 |
| LVI | 2.05 | 1.59–2.63 | 0.84 | 0.30–2.36 | 2.13 | 1.63–2.80 | 0.23 | 0.03–1.90 | 1.94 | 1.16–3.26 | 0.49 | 0.07–3.64 | 1.96 | 1.32–2.91 |
| ECS | 1.16 | 0.89–1.51 | 1.16 | 0.89–1.52 | 1.47 | 0.93–2.34 | 1.46 | 0.97–2.22 | ||||||
| Margin <5 mm | 1.76 | 1.37–2.27 | 1.29 | 0.66–2.53 | 1.85 | 1.41–2.43 | 4.28 | 1.18–15.53 | 1.19 | 0.68–2.08 | 1.05 | 0.36–3.03 | 1.85 | 1.20–2.86 |
| Late stage | 2.28 | 1.71–3.03 | ||||||||||||
Abbreviations: RMT, retromolar trigone; HR, hazard ratio; CI, confidence interval; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; PNI, perineural invasion; LVI, lymphovascular invasion; ECS, extra-capsular spread.